Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENLOGA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Treatment of urinary tract infections due to susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris,Treatment of acute otitis media in children,Treatment of acute exacerbations of chronic bronchitis in adults,Treatment of enteritis caused by Shigella flexneri or Shigella sonnei,Prophylaxis and treatment of Pneumocystis jirovecii pneumonia,Treatment of traveler's diarrhea,Treatment of toxoplasmosis
Prevention of pregnancy
350 mg orally once daily with food.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (Cr Cl 30-50 m L/min)
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Sulfamethoxazole is primarily metabolized via N-acetylation (N-acetyltransferase 2) and glucuronidation. Trimethoprim is metabolized primarily by oxidative O-demethylation (CYP3A4, CYP1A2) and conjugation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
98% bound primarily to albumin
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.15-0.3 L/kg, indicating limited extravascular distribution
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 92% (high first-pass metabolism; extensive absorption)
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR ≥45 m L/min: no adjustment; GFR 30-44 m L/min: 350 mg every other day; GFR <30 m L/min or ESRD: not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific dose adjustment recommended; monitor renal function closely in patients ≥65 years.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Fatal hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias have been reported with sulfonamides. JENLOGA is contraindicated in patients with a history of hypersensitivity to sulfonamides or trimethoprim.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Fatal hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash,Hematologic toxicity including agranulocytosis, aplastic anemia; monitor CBC regularly,Hepatic necrosis; discontinue if signs of liver injury occur,Severe renal impairment (Cr Cl <15 m L/min); avoid use,Potential for hyperkalemia in patients with renal dysfunction or those on potassium-sparing diuretics,Risk of folate deficiency; monitor folate levels in chronic therapy,Photosensitivity; avoid prolonged sun exposure
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Hypersensitivity to sulfonamides or trimethoprim,History of drug-induced immune thrombocytopenia with prior sulfonamides,Megaloblastic anemia due to folate deficiency,Severe renal impairment (Cr Cl <15 m L/min) unless for Pneumocystis jirovecii pneumonia treatment,Pregnancy at term and nursing mothers (due to potential for kernicterus in neonates),Concomitant use with dofetilide (increases risk of arrhythmias)
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Take with or without food. High-fat meals may delay absorption but no significant clinical impact. Avoid grapefruit and grapefruit juice as they may alter drug levels.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-trimester exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal hypoglycemia.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Not recommended during breastfeeding. M/P ratio not established; drug is excreted in human milk. Potential for serious adverse reactions in nursing infants.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Dose adjustments required due to increased volume of distribution and enhanced clearance; monitor trough levels and adjust to maintain therapeutic range. Consider 30-50% dose increase in third trimester.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Jenloga (cenobamate) is a tetrazole-derived antiepileptic drug. Titrate slowly to reduce risk of severe hypersensitivity reactions, including DRESS syndrome. Monitor for QT shortening on ECG. Dose adjustments needed in renal impairment. Consider lower starting dose in patients with hepatic impairment.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take exactly as prescribed; do not stop suddenly without medical advice.,Report any rash, fever, or swollen lymph nodes immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception; drug may cause fetal harm.,Notify healthcare provider if you become pregnant or plan to.,May cause dizziness or somnolence; avoid driving until effects known.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENLOGA vs ALYACEN 7/7/7, answered by our medical review team.
JENLOGA is a Oral Contraceptive that works by JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENLOGA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENLOGA is: 350 mg orally once daily with food.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENLOGA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENLOGA is classified as Category C. Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-tr. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.